David Flynn

The National Institutes of Health (NIH)'s Clinical and Translational Science Awards (CTSA) consortium aims to accelerate translational processes that move discoveries from bench to bedside. The coronavirus disease 2019 (COVID‐19) pandemic presented unmatched challenges and applications for CTSA hubs nationwide. Our study used bibliometrics to assess features of COVID‐19 publications supported by the national CTSA program to characterize the consortium's response to the pandemic. Our goal was to understand relative scientific influence, collaboration across hubs, and trends in research emphasis over time. We identified publications from NIH's curated iSearch COVID‐19 Publication Portfolio from February 2020 to February 2023; 3234 peer‐reviewed articles relevant to COVID‐19 cited a CTSA grant. All 66 CTSA hubs were represented, with large‐size and longstanding hubs contributing more publications. Most publications cited UL1 grants, 457 cited KL2/TL1 training grants, and 164 cited multiple hub grants. Compared to a random sample of non‐CTSA‐supported COVID‐19 publications, the CTSA portfolio exhibited greater clinical relevance, more human research, and higher altmetric and citation influence. Results were similar for multi‐hub publications involving networked initiatives like multi‐site clinical trials or the National COVID‐19 Cohort Collaborative. Shifts from molecular/cellular‐oriented research toward human‐oriented research over time were evident, demonstrating translation in action. Results illuminate how the CTSA consortium confronted the pandemic through high‐quality projects oriented toward human research, working across hubs on high‐value collaborations, advancing along the translational spectrum over time. Findings validate CTSA hubs as critical support structures during health emergencies.